Gemcitabine plus docetaxel versus capecitabine plus docetaxel forpatients with anthracycline-pretreated metastatic breast cancer: A review of the results of a European Phase III trial

European Journal of Cancer, Supplement

Volumn 3, Issue 5, 2005, Pages 17-21

  Chan, Stephen ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Capecitabine plus docetaxel; Gemcitabine plus docetaxel; Metastatic breast cancer

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; DOCETAXEL; GEMCITABINE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 33645538717     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(05)82020-8     Document Type: Article

References (16)

1. Available from Ferley J., Bray F., Pisani P., and Parkin D.M. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide (accessed July 2005) IARC CancerBase, version 2.0 2004 IARCPress Lyon
2. Early breast cancer trialists' collaborative group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1617 1687
3. Nabholtz J.M., Senn H.J., and Bezwoda W.R. Prospective randomised trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline containing chemotherapy. 304 Study Group J Clin Oncol 17 1999 1413 1424
4. Chan S., Friedrichs K., and Noel D. Prospective randomized trial of docetaxel versus doxombicin in patients with metastatic breast cancer. The 303 Study Group J Clin Oncol 17 1999 2341 2354
5. O'Shaughnessy J., Miles D., and Vukelja S. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with metastatic breast cancer: Phase III trial results J Clin Oncol 20 2002 2812 2823
6. Laufman L., Spiridonidis C., and Pritchard J. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a Phase II trial Ann Oncol 12 2001 1259 1264
7. (abst 1956) Brandi M., Giotta F., and Vici P. Salvage chemotherapy with docetaxel and gemcitabine in metastatic breast cancer: preliminary results of a multicentre Phase II trial of GOIM Proc Am Soc Clin Oncol 20 2001
8. (abst 1978) Kornek G., Raderer M., and Fiebiger W. Treatment of metastatic breast cancer with docetaxel and gemcitabine plus human granulocyte colony stimulating factor Proc Soc Am Clin Oncol 20 2001
9. Fountzilas G., Nicolaides C., and Bafaloukos D. Docetaxel and gemcitabine in anthracycline resistant metastatic breast cancer: a Hellenic Cooperative Oncology Group Phase II study Cancer Invest 18 2000 503 509
10. Mavroudis D., Malamos N., and Alexopoulos A. Salvage chemotherapy in anthracycline pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicentre Phase II trial. Greek Breast Cancer Co-operative Group Ann Oncol 10 1999 211 215
11. Alexopoulos A., Tryfonopoulos D., and Karamouzis M.V. Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer Ann Oncol 15 2004 95 99
12. (abst 510) Albain K.S., Nag S., and Calderillo-Ruiz G. Global Phase III study of gemcitabine plus paclitaxel (GT) vs paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival Proc Am Soc Clin Oncol 23 2004
13. (abst 581) Chan S., Romieu J., and Huober T. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anythracycline pretreated metastatic breast cancer (MBC) patients(pts): results of a European Phase III study Proc Am Soc Clin Oncol 2005
14. (abst 400) O'Shaughnessy J., Vukelja S., and Moiseyenko V. Retrospective evaluation of the impact of dose reduction in patients treated with capecitabine (capecitabine) Proc Am Soc Clin Oncol 1999
15. (abst 402) Michaud L., Gauthier M., and Wojdylo J. Improved therapeutic index with lower dose capecitabine in metastatic breast cancer patients Proc Am Soc Clin Oncol 18 1999
16. (abstr 2) Sledge G.W., Neuberg D., and Ingle J. Phase III trial of doxorubicin (A) vs paclitaxel (T) vs doxorubicin + paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC)patients. An Intergroup trial Proc Am Soc Clin Oncol 16 1997